GB202101780D0 - Epitopes and Antibodies - Google Patents

Epitopes and Antibodies

Info

Publication number
GB202101780D0
GB202101780D0 GBGB2101780.1A GB202101780A GB202101780D0 GB 202101780 D0 GB202101780 D0 GB 202101780D0 GB 202101780 A GB202101780 A GB 202101780A GB 202101780 D0 GB202101780 D0 GB 202101780D0
Authority
GB
United Kingdom
Prior art keywords
epitopes
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2101780.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oblique Therapeutics AB
Original Assignee
Oblique Therapeutics AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oblique Therapeutics AB filed Critical Oblique Therapeutics AB
Priority to GBGB2101780.1A priority Critical patent/GB202101780D0/en
Priority to KR1020227032962A priority patent/KR20220157400A/en
Priority to JP2022550709A priority patent/JP2023514423A/en
Priority to EP21710890.1A priority patent/EP4110388A1/en
Priority to BR112022016643A priority patent/BR112022016643A2/en
Priority to AU2021227406A priority patent/AU2021227406A1/en
Priority to US17/801,391 priority patent/US20230109318A1/en
Priority to PCT/EP2021/054614 priority patent/WO2021170684A1/en
Priority to IL295788A priority patent/IL295788A/en
Priority to MX2022010306A priority patent/MX2022010306A/en
Priority to CN202180030709.4A priority patent/CN115443153A/en
Priority to CA3171833A priority patent/CA3171833A1/en
Publication of GB202101780D0 publication Critical patent/GB202101780D0/en
Ceased legal-status Critical Current

Links

GBGB2101780.1A 2020-02-24 2021-02-09 Epitopes and Antibodies Ceased GB202101780D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB2101780.1A GB202101780D0 (en) 2021-02-09 2021-02-09 Epitopes and Antibodies
KR1020227032962A KR20220157400A (en) 2020-02-24 2021-02-24 KRAS epitopes and antibodies
JP2022550709A JP2023514423A (en) 2020-02-24 2021-02-24 KRAS epitopes and antibodies
EP21710890.1A EP4110388A1 (en) 2020-02-24 2021-02-24 Kras epitopes and antibodies
BR112022016643A BR112022016643A2 (en) 2020-02-24 2021-02-24 EPITOPES AND ANTIBODIES AGAINST KRAS
AU2021227406A AU2021227406A1 (en) 2020-02-24 2021-02-24 Kras epitopes and antibodies
US17/801,391 US20230109318A1 (en) 2020-02-24 2021-02-24 Kras epitopes and antibodies
PCT/EP2021/054614 WO2021170684A1 (en) 2020-02-24 2021-02-24 Kras epitopes and antibodies
IL295788A IL295788A (en) 2020-02-24 2021-02-24 Kras epitopes and antibodies
MX2022010306A MX2022010306A (en) 2020-02-24 2021-02-24 Kras epitopes and antibodies.
CN202180030709.4A CN115443153A (en) 2020-02-24 2021-02-24 KRAS epitopes and antibodies
CA3171833A CA3171833A1 (en) 2020-02-24 2021-02-24 Kras epitopes and antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2101780.1A GB202101780D0 (en) 2021-02-09 2021-02-09 Epitopes and Antibodies

Publications (1)

Publication Number Publication Date
GB202101780D0 true GB202101780D0 (en) 2021-03-24

Family

ID=74878972

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2101780.1A Ceased GB202101780D0 (en) 2020-02-24 2021-02-09 Epitopes and Antibodies

Country Status (1)

Country Link
GB (1) GB202101780D0 (en)

Similar Documents

Publication Publication Date Title
IL289585A (en) Dll3-targeting antibodies and uses thereof
EP3708575A4 (en) Thioredoxin 1 epitope and monoclonal antibody specifically binding thereto
SG11202112112UA (en) Anti-galectin-9 antibodies and uses thereof
IL289488A (en) Monoclonal antibodies that bind egfrviii and their use
IL289656A (en) Anti-tigit antibodies and application thereof
IL291027A (en) Anti-steap1 antibodies and uses thereof
IL281272A (en) Humanized anti-c5 antibodies and uses thereof
IL310938A (en) Anti-ccr8 antibodies and uses thereof
GB202017058D0 (en) Antibodies and uses thereof
IL281608A (en) Anti-human cd45rc antibodies and uses thereof
EP4056586A4 (en) Epitope of regulatory t cell surface antigen, and antibody specifically binding thereto
IL291550A (en) Anti-il-27 antibodies and uses thereof
IL291546A (en) Anti-kir3dl3 antibodies and uses thereof
EP4132974A4 (en) Anti-cd98 antibodies and uses thereof
EP4274851A4 (en) Anti-gprc5d monoclonal antibodies and uses thereof
IL308808A (en) Anti-ccr8 antibodies and uses thereof
IL307940A (en) Anti-adgre2 antibodies and uses thereof
IL307267A (en) Anti-cd122 antibodies and uses thereof
GB201918103D0 (en) Epitopes and antibodies
IL291280A (en) Anti-cd371 antibodies and uses thereof
IL286803A (en) Anti-tauc3 antibodies and uses thereof
EP4169950A4 (en) Anti-lilrb1 antibody and uses thereof
GB202101780D0 (en) Epitopes and Antibodies
GB202019522D0 (en) Epitopes and antibodies
GB201902590D0 (en) Antibodies and uses thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)